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ABSTRACT
To optimize the growth promoting effect of growth hormone (GH), 
65 previously untreated girls with Turner syndrome (TS), chronolog­
ical age (CA) 2-11 yr, were randomized into 3 dosage regimen groups:
A, B, and C, w ith a daily recombinant-human GH dose during 4 study 
years of 4-4-4-4, 4-6-6-6, and 4-6-8-8 IU/m2 b.s.
The first GH dosage increase in groups B and C resulted in a 
significantly higher mean height velocity (HV) compared with con­
stant dose group A. During the third year, when the dose was raised 
again only in group C, mean HV was significantly higher in  groups 
B and C than in group A, and in group C compared with group B. In 
year 4 only group C mean HV remained significantly higher th a n  
group A. The pattern  of change in HSDSCA (Dutch-Swedish-Danish 
Turner references) was identical; however, in  year 4 m ean AHSDSCa 
in group B also remained significantly higher th an  group A. After 4 yr 
GH treatment, the following was determined. 1) The m ean AHSD3ca 
was significantly higher for groups B and C compared with group A, 
but not significantly different between groups B and C. 2) Although 
significantly higher compared with estim ated values for un trea ted  
Dutch girls with TS, bone m aturation of the GH treated  girls was not 
significantly different between groups. 3) I t  was positively related 
with the degree of bone age (BA) retardation a t s ta r t of study and 
negatively with baseline CA. 4) Both the modified Index of Potential
H eight (m IPH RUS) and a  recently developed Turner-specific final 
height (FH) prediction method (PTSRUs)* based on regression coeffi­
cients for H, CA, an d  bone age, showed significant increases in mean 
FH  prediction, w ithout significant differences betw een groups. 
PTSrus values were m arkedly h igher th a n  the  m IPH RUS values.
Dose dependency could be shown for the  area under the  curve
(AUC) for GH, bu t AHSDSCa was n ° t  linearly related  w ith  AUC. 
Baseline GH binding protein (BP) levels w ere in 84% of the  cases 
w ithin th e  norm al age range; the  decrease in  m ean levels after 6 
m onths GH was no t significant. M ean insulin-like growth factor I 
(IGF-I) an d  IGFBP-3 p lasm a levels increased significantly, w ithout 
significant differences between groups. AHSDSca during GH was 
dependent on IGF-I p lasm a levels a t  baseline and during the study 
period, |3-0.002 and /3-0.0004. Thus, a stepwise GPI-dosing approach 
reduced th e  “w aning” effect of the growth response after 4 y r trea t­
m ent w ithout undue bone m aturation . FH  prediction was not signif­
icantly different betw een trea tm en t groups. Irrespective of the GH 
dose used, in itiation of GH trea tm en t a t a younger age was beneficial 
after 4 y r  GH when expressed as actual cm gained or as gain in FH 
prediction, bu t was not statistically  significant when expressed as 
AHSDSpA over th e  study period. ( J  C lin  E n d o c r in o l  M e ta b  81: 4013- 
4021,1996)
STUNTED growth is an almost invariable hallmark of girls with Turner syndrome (TS). Although these girls are 
not clearly GH-deficient (GHD) (1-4), GH therapy results in
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a marked increase of height velocity (HV) (5-7). Studies in 
GHD patients (8-10) and in TS (5-7,11-13) have shown that 
the growth response to GH treatment is dependent on the 
dose and frequency of administration. Frasier et al. (14) re­
ported in a 1 yr, parallel study in prepubertal GHD children 
that doubling the GH dose of 30 mU / kg thrice weekly im 
resulted only in a 1.3-fold increase of the first year HV. Also 
in TS, daily GH injections were more effective than the same 
weekly dosage in two or three weekly injections (12). In the 
past years, the most commonly used GH dosages in TS varied 
from 2 -4  IU /m 2 body surface/day sc (5-7, 12, 15), where 4 
IU /m 2 is equivalent to 0.045 mg /kg. In studies using GH 
dosages only, up to 4 IU /m 2/day, the growth rate out- 
weighed the accelerated bone maturation (13,16), and thus,
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final height (FH) prediction improved more than with lower 
GH doses (5,7,12,15). An earlier GH treatment study of girls 
with TS in the Netherlands (16) showed a doubling of the HV 
in the first year of treatment with 4 IU G H /m 2/day  com­
pared with pretreatment values. However, this increase 
could not be maintained during the subsequent years of 
treatment. This so-called "waning" effect has also been re­
ported by others (10,17). In GHD patients, a similar effect is 
observed, which can be overcome by a 2- to 3-fold increase
of the GH dose (10, 18).
Furthermore, studies in GHD patients have demonstrated 
the importance of early diagnosis and therapy. GH treatment 
prevented further loss of stature but could not make up the 
deficit at diagnosis (19). The previous Dutch studies of 
Turner syndrome confirmed that the growth response in 
younger girls was better than in older girls (12, 13, 16). In 
contrast to the logarithmic relationship between GH dose, 
given thrice weekly im, and HV in GHD children, the effect 
of GH on insulin-like growth factor (IGF)-I plasma levels has 
been shown on a linear scale between 0 and 3 IU GH / m2 / day 
in GHD adults (20). In the present study of TS, this concept 
is extended to the 4 -8  IU /m 2/day  GH range.
To optimize GH treatment in TS, we investigated whether 
1) a yearly stepwise increment of the GH dose could maintain 
or augment the initial increase in HV and thereby improve 
FH prediction. In addition, we investigated whether 2) treat­
ment from a young age onwards could improve FH predic­
tion. Moreover, in a subgroup of 12 girls the GH-IGF-T axis 
was studied in detail under GH treatment.
Subjects and Methods
Study group
Sixty-eight previously untreated girls with TS were enrolled in a 4-yr, 
multicenter GH dose-response study. The diagnosis was confirmed by 
lymphocyte chromosomal analysis. Clinical data and karyotype of the 
girls are listed in Table 1. Inclusion criteria were: a chronological age 
(CA) between 2 and 11 yr, height below the 50th percentile for Dutch 
children (21), and a normal thyroid function. Exclusion criteria were: 
associated endocrine and / or metabolic disorders, growth failure caused
TABLE 1. Baseline data  for each trea tm en t group
Group A Group B Group C
Number of girls 22 22 21
CA (yr) 6.1 (2.1) 6.7 (2.4) 6.5 (2,4)
RUS BA (yr) 5.5 (2.2) 6.0 (2.5) 5.8 (2.4)
HSDSCA (RvW) -2 .7 (0.9) “ 2.4 (1.0) -2 .6 (1.0)
HSDSCA (DSD) 0.06 (1.03) 0.42 (1.05) 0.18 (1.06)
HVSDSCA (DSD) 0.32 (0.80) 0.08 (0.91) 0.16 (0.71)
mIPHRUS (cm) 147.8 (7.7) 148.0 (4.8) 147.4 (5.5)
PTSkus (cm) 145.6 (5.9) 147.6 (5.2) 146.3 (5.0)
MPH (cm) 169.4 (5.9) 170.6 (6.0) 169.7 (5.7)
BMI-sd score 0.24 (1.20) 0.27 (1.33) 0.20 (1.29)
Karyotype: 45,X 18 (82%) 21 (96%) 16 (76%)
Karyotype: other 4 (18%) 1 (4%) 5 (24%)
maxGH (ATT) mU/L 23.5 (16.6) 20.4 (15.2) 25.6 (16.4)
Values are given as m ean (s d ). CA, chronological age; RUS BA, 
RUS-bone age; SDS standand deviation score; H, height; HV, height 
velocity; RvW, Dutch reference standard  for girls; DSD, Dutch-Swed- 
ish-Danish Turner references; m IPHRUS, modified Index of Potential 
Height; PTSRUS, Turner-specific final height prediction using RUS 
bone age; MPH, m idparental height; BMI, body mass index-SD S; 
maxGH (ATT), maximum GH plasm a concentration after arginine 
stimulation.
by other disorders or emotional deprivation, hydrocephalus, previous 
use of drugs that could interfere with GH therapy, and Tanner puberty 
stage of at least B2 (22). No provision was made with regard to the 
baseline GH stimulation tests.
Study design
The girls were randomized into three GH dosing groups with strat­
ification according to CA and height standard deviation score (HSDSCA):
A. (n =  23) 4 IU /m 2 body surface (equivalent to 0.045 mg/kg)/day 
for 4 yr,
B. (n = 23 ) 4 IU/m2 in the first year, followed by 6 IU/m2/day during 
the second through fourth yr,
C. (n = 22) 4 IU/m2 in the  first year, 6 IU/m2 in the second year, 
and 8 IU/m2/day during the third and fourth yr.
Biosynthetic (B)-hGH (Norditropin, Novo Nordisk A/S, Denmark) 
was given sc at bedtime by means of a pen injection system (Nordiject 
24). None of the girls received estrogens during the 4-yr study period. 
Written, informed consent was obtained from the parents or custodians 
of each child. The study protocol was approved by the Ethics Committee 
of each participating center.
Growth evaluation
Height measurements were determined at baseline and three times 
per. month by one investigator (A,T.) according to the methods of Cam­
eron (23), using a Harpenden stadiometer. Height was expressed as 
SD-Score for CA (HSDSCA/ HVSDSCA) using the Dutch-Swedish-Danish 
(DSD) Turner data (24) or reference data of normal Dutch (21) girls. The 
gain in height for untreated girls with TS was estimated from the equa­
tions of the DSD Turner data (24), in which the height of an average girl 
with TS is indicated by her CA. Midparental height (MPH) was adapted 
for Dutch reference data (21) with the addition of 3 cm for secular trend: 
MPH = 1 j  2 X (Hmother + H falher -  12) + 3 cm. The degree of obesity 
was expressed as body mass index (BMI) s d  score (25). Bone age (BA) 
was determined by one investigator (A.T.) according to Tanner & White- 
house radius, ulna, short-bones (RUS) score (26). Bone maturation 
(ABA/ ACA) was compared with estimated values from the equations of 
untreated Dutch Turner girls (27); in these equations the BA of an 
average girl with TS is indicated by her CA. FH prediction was estimated 
using the modified Index of Potential Height (mIPHRUS) method (28,29) 
and a recently developed Turner-specific method (PTSRUS) (29). Both 
methods comprise Dutch Turner references. Analoguous to the Tanner 
and Whitehouse mark 2 FH prediction method for normal children, the 
PTS method gives smoothed regression coefficients for H, CA, and BA.
Biochemical parameters
At baseline all girls underwent a GH provocation test. Arginine 0.5 
g /kg  body weight was infused in 30 min. Blood samples were drawn 
at 15-min intervals from —15 to +60 min and every 30 min during the 
second hour.
At baseline, 6 months after initiation of GH, and 6 months after each 
GH dosage increase, a 24-h GH profile was performed in a subgroup of 
12 girls of group C. Starting at 0830 in the morning, blood was with­
drawn from an indwelling venous catheter with a heparin lock. Blood 
was collected every 20 min for GH measurement, and at the start a single 
additional sample was obtained for measurement of IGF-I and IGFBP-3, 
The girls kept normal diets served at hospital mealtimes and kept normal 
activity and sleeping habits. GH was injected before going to bed. At the 
above study time points blood was collected from all girls for the de­
termination of IGF-I and IGFBP-3, and at 42 and 48 months only for 
IGF-I. GH binding protein (GHBP) was determined at baseline and 6 
months after initiation of GH therapy. All blood samples were stored on 
ice for no more than 3 h  until centrifugation. The plasma samples were 
frozen (-20  C) until assayed.
Hormone assays
The RIA measurements of plasma GH, IGF-I, and IGFBP-3 were 
performed as described previously (30-32). The 95th percentile for peak 
pubertal levels in a normal female population for IGF-I and IGFBP-3 are
■
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700 ju,g/L and 5 m g/L, respectively. Plasma GH binding protein (GHBP) 
was determined by ligand-mediated immu nofunctional assay (LIFA) 
(33, 34). All measurements were performed in the same laboratories.
Statistical analyses
Results are expressed as mean ( s d ), unless indicated otherwise. Dif­
ferences between groups were tested by Student's t-tests or by a oneway 
ANOVA (followed by the Student-Newman-Keuls test for multiple 
comparisons between groups at the P = 0.05 level). Differences between 
points in time were tested by paired Student's Ntests. The Kruskal-Wallis 
test was used to test for differences between stimulated maximum GH 
levels and Tanner breast-stage groups, the Chi-square test for differences 
between karyotype groups (45, X, and others). Correlations were tested 
with Pearson's linear correlation coefficient. For this purpose, IGF-I and 
IGFBP-3 plasma levels were transformed into log-values. To study the 
relation between growth response variables (the change in HSDSCA, 
HVSDS, bone maturation, or PTSRU5) and growth parameters measured 
at baseline [CA, BA, BA retardation (= CA-BA), HV, maximal GH peak 
after stimulation, s d  scores for BMI, H, and HV], adjusted for the dose 
regimen (i.e. group), multiple linear regression (MLR) analyses were 
used. Statistical procedures were performed using the SPSS/PC + pro­
gram version 4.0 (SPSS Inc, Chicago, IL). A repeated measures ANOVA 
model (adjusted for dose-increment steps and duration of treatment) 
was used to determine the influence of baseline IGF-I levels on those 
during GH therapy and of IGF-I levels (at baseline and during GH 
therapy) on HSDSCA during GH therapy, using BMPD module 5V. A P 
value of less than 0.05 was considered significant.
The spontaneous 244i GH profiles at baseline were analyzed with the 
Pulsar program developed by Merriam and Wachter and described 
previously (30). The area under the curve (AUC) was determined after 
the GH injection at 1600 h using the trapezoideal rule. The total body 
clearance was calculated from the injected dose divided by the AUC. The 
time interval from GH injection to maximum GH levels was recorded 
as Tmax. To determine the elimination half-time (t1/2) a linear regression 
analysis was performed on the GH levels starting from 1 h after T,max'
Results
Clinical data
In each group only one girl dropped out of the study for 
the following reasons: noncompliance, alleged increase of 
muscle mass and decline in school performance, and desire 
to initiate estrogen therapy before the end of the study pe­
riod. Eight girls changed during the course of the study from 
Tanner puberty stage B1 to B2, at a median age of 13.2 (range 
10.9-15.0) yi\ Their distribution among the treatment groups 
A, B, and C was 2, 4, and 2 girls, and among karyotypes (45, 
X and others) 4 and 4 girls, respectively. There were no 
significant differences between these girls and the girls with­
out signs of endogenous estrogen production with respect to 
growth response and bone maturation after 4 yr GH therapy 
within each dose group, The number of adverse events was 
small, all were mild and transient.
Growth response
Compared with pretreatment, mean HV increased signif­
icantly for all three groups from about 6 cm /yr to 10 cm /yr 
in die first year of GH therapy. Thereafter, a waning of the 
growth response was observed (Fig. 1). In the second year 
mean HV in groups B and C on a 50% higher GH dose were 
significantly higher compared with group A. When subse­
quently, in group C only, the dose was increased once again, 
mean HV in groups B and C were both significantly higher 
than in group A, but in group C also significantly higher 
compared with group B. In the fourth year of GH treatment
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only in group C the mean HV remained significantly higher 
than group A. During the first year of treatment 29% of all 
girls managed to double their HV.
If the growth response is represented as change in 
HVSDSca relative to prestudy values (see Table 1), 
AHVSDSca in groups B and C was significantly higher than 
in group A in the second through fourth year of GH therapy. 
However, in the third and fourth year AHVSDS in group C 
was not significantly different from group B.
After the first dose-increment for both groups B and C, the 
change in HSDSCA from the first year was significantly 
higher for the combined groups B and C compared with 
group A (P <  0.0001). The second dose-increment in the third 
year of treatment, as well as in the combined third and fourth 
year, resulted in a significantly higher change from year 2 in 
HSDSca for group C compared with group B, P values 0.04 
and 0.02. The increase in mean HSDSCA was highest in the 
first year of GH (>1 s d s ), without a difference between 
groups (Fig. 2). In the subsequent years of treatment, the 
change in mean HSDSCA showed the same pattern as that of 
HV. The mean increment in HSDSCA over 4 yr was signifi­
cantly higher for groups B and C compared with group A. 
However, the gain was not significantly different between 
groups B and C (Table 2). The change in HSDSCA after 4 yr 
was unrelated to karyotype. When the gain in height was 
corrected for the estimated gain for untreated girls, the re-
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TABLE
Group A Group B Group C
AHSDSCA (DSD) 2.46 (0.53) 2.91 (0.54)° 3.07 (0.57)" 0.004
height gain (cm) 12.4 (2.8) 15.3 (3,1)“ 15,7 (2 .5 f 0,0004
HVSDSca (DSD) (y4-prestudy) 1.60 (0.97) 2.43 (1.22)° 2.62 (0.99)° 0.007
ABA/ACA (y/4y) with GH 5.2 (0,7) 5.4 (0.9) 5.3 (1.0) NS
ABA/ACA (y/4y) untreated 4.0 (0.5) 3.8 (0.6) 3.9 (0.6) NS
AmlPHftus (cm) 4.9 (4.8) 6.6 (3.1) 7.1 (4.5) NS
APTSrus (cm) 12.3 (3.8) 14.1 (3.1) 14.7 (3.5) NS
P, level of significance in a oneway ANOVA; A, change during a period of time for a variable; height gain, gain in cm over estimated untreated 
values; ITV, height velocity; s d s , standard  deviation score; DSD, Dutch-Swedish-Danish Turner references; ABA/ACA, bone maturation 
(RUS-score): change in BA during 4 years GH treatm ent; untreated values were estimated using Dutch Turner references; mIPHRlJS, modified 
Index of Potential Height; PTSRUS) Turner-specific final height prediction using RUS bone age. 
a Significantly different from group A.
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suits were similar (Table 2 and Pig. 3). The range of the gain 
in height over estimated untreated values for all girls was 
5.5-21.9 cm; for four girls (all Group A), it was below 10 cm.
Bone maturation
The change in RUS BA over the change in CA was not 
significantly different between groups over 4 yr (Table 2), nor 
during any individual year of treatment. The mean values 
differed somewhat between the years: for all groups the 
highest advance was found during the third year and the 
lowest during the fourth year of GH (data not shown). Com­
pared with estimated values for untreated TS girls, bone 
maturation of the GH treated girls was significantly higher 
in every year, except for group A in the second and fourth 
year; for 4-yr results see Fig. 3. There was no significant 
difference in the change in bone maturation over 4 yr be­
tween the girls with breast-stage B1 and B2 within groups. 
Bone maturation after 4 yr of treatment was positively related 
with the degree of BA 1'etardation at start of study (/3: 0.12) 
and negatively with baseline CA (0: —0.04).
Final height (FH) prediction
Mean FH prediction increased significantly for all groups 
after 4 yr GH treatment (Table 2); values with the FTSrus 
method were markedly higher compared with the mIPHRUS 
method. Significant differences between groups for the 4 yr 
change in either FH prediction method were not found,
though mean values with both methods in groups B and C 
were higher than those in group A.
GH measurements
Baseline Arginine-stimulated GH plasma levels ranged 
from 3-74 mU/L (Table 1). The stimulated GH levels (mU/L) 
were subdivided in the following level-ranges: less than 10, 
at least 10 and less than 20, and at least 20, with 9,28,31 girls, 
respectively. These numbers were similarly distributed 
among the 3 treatment groups. The girls with maximum 
stimulated GH levels below 20 mU / L did not differ signif­
icantly from those with normal stimulated levels (>20 
mU/L) in their growth response expressed as the change in 
HSDSCA after 4 yr of GH treatment. Maximum stimulated 
GH levels were significantly negatively correlated with 
BMI-sd score at baseline (r = -0.31, P = 0.01). At baseline, 
the spontaneous and stimulated maximum GH levels in 
group C were not significantly different and were positively 
correlated (r = 0.5, P = 0.05).
Table 3 includes some of the calculated variables of the 
spontaneous 24-h GIT profiles of 12 girls of Group C (at 
baseline). There was no correlation between any of these 
characteristics and prestudy HSDSCa* Furthermore, the 
characteristics of the 24-h GH profile tests 6 months after 
each dose-increment are shown. There was a significant, 
dose-dependent increase of the maximum GH level and 
the AUC. In contrast, the Tmax, the clearance, and the 
elimination half-life were not significantly different be­
tween the 3 GH doses. The latter is indicated by the par­
allelism between the curves after the maximum has been 
reached (Fig. 4).
GH binding protein (GHBP)
Baseline measurements showed no differences between 
groups (Table 4), the mean (s d ) for all girls being 229.4 (127.1) 
pmol/L. Compared with girls in a normal population (34), 
85% of the study group had GHBP levels within the normal 
age range, 9 girls (14%) had levels that were above normal, 
and only 1 girl (l%)had levels below normal. Baseline GHBP 
levels as well as the change from baseline after 6 months were 
not significantly different between the girls with stimulated 
GH levels above or below 20 mU/L. GHBP levels after 6 
months treatment did not differ significantly from baseline.
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TABLE 3. Median (range) values for characteristics of the  24-h GH profili 
Pulsar) and 6 months after each dose-increment step (see M e th o d s  section)
Baseline 4 IU/m2/day 6 IU/m2/day 8 IU/m2/day
Number of peaks 10 (8; 13)
Mean GH (mU/L) 4.3 (1.64;6.78)
Max GH (mU/L) 23.5 (8;42) 63 (27;127) 113 (57;174)a 197 (101;405)a,i
AUC (mU/L x  24 h) 99.1 (39.8;160.3) 341 (160;157) 570 (352;896)a 962 (554;1530)a’6
Clearance (mL/min) 420 (224;680) 412 (203;568) 362 (214;566)
t 1/2 (hrs) 0.5 (0.2;0.7) 0.5 (0.3;0.7) 0.5 (0.2;0.9)
Tmnx (hrs) 2.9 (1.3;4.3) 3.2 (1.3;6.Q) 3.2(1.7;5.3)
No of peaks, num ber of peaks; mean GH, overall m ean GH plasm a concentration; m ax GH, m axim um  GH plasm a concentration; AUC, area 
under the time-concentration curve; clearance, total body clearance; t 1/2, elim ination half-time; T nmx, tim e to peak  value. Values in  parentheses 
are high and low.
a Significantly greater compared with 4 IU/m2/day a t P  <  0.05 level. 
b Significantly greater compared with 6 IU/m2/day a t P  <  0.05 leveL
The ratio of IGF-I and IGFBP-3 levels showed an increase 
over time, but there were no significant differences between 
groups. Log-values of IGF-I and IGFBP-3 levels both at base­
line and their change after 30 months revealed a significant 
correlation (r = 0.76, P <  0.0001 and r = 0.25, P = 0.04, 
respectively).
Time' (hrs)
Fig. 4. Mean 24-h GH plasma curves (logarithmic scale) vs, time 
for each of the three GH dosages ( 4 IU —E3—, 6 IU  - —f- - *, and 8 I U  
—<$■—) employed in a subgroup of 12 girls of Group C, 6 m onths after 
initiation and following each GH dose-increment.
IGF-I and IGF binding protein-3 (IGFBP-3)
At each time-point large interindividual differences ex­
isted within groups (Table 4). Mean baseline IGF-I level of 
group B was higher compared with the other groups. Within 
groups, each point in time was significantly higher than the 
previous, except for 30 months (all groups) and 42 months 
(group B). Not until 30 months after the start of therapy did 
IGF-I levels (adjusted for baseline levels) for groups B and C 
become significantly higher compared with group A (P < 
0.004), but at 48 months only group C was still significantly 
higher than group A (P = 0.008). The repeated measures 
model showed that the change in IGF-I levels during GH 
therapy was dependent on the dose, the duration of treat­
ment, and baseline IGF-I level.
At baseline, mean IGFBP-3 levels for group B were higher 
compared with the other two groups. After adjustment for 
baseline, IGFBP-3 levels were not significantly different be­
tween groups (Table 4). Mean IGFBP-3 levels only increased 
significantly after 6 months of treatment (P <  0.0001). At the 
end of study 31% of the girls had plasma IGF-I levels and 35% 
had IGFBP-3 levels higher than the 95th percentile for normal 
girls at the pubertal peak. There were no differences between 
treatment groups.
Determinants o f growth response
Multiple Linear Regression analyses showed that there 
were no significant relationships between 1) HVSDSCA in the 
fourth year GH (dependent variable) and pretreatment 
HVSDS; 2) the change in HSDSCA after 4 yr GH (dependent- 
variable) and baseline: CA, BA RUS, BA retardation, HSD- 
SCA, or Arginine-stimulated maximum GH levels (/3 = 
—0.008; P = 0.07); and 3) prestudy HV or HVSDS and base­
line IGF-I, or IGFBP-3 levels, or between the IGF-I to IGFBP-3 
ratio. However, the 4-year change in HSDSCA was signifi­
cant, negatively related to baseline IGF-I and IGFBP-3 levels 
and their ratio (/3-values —0.006, —0.32, and —0.015, respec­
tively); even when the baseline IGF-I and IGFBP-3 concen­
trations were expressed as s d  score relative to CA only for the 
girls with a baseline CA below 10 yr (n = 64). The change in 
HSDSca after 30 or 48 months GH treatment was also sig­
nificant, positively related to the change in IGF-I, and IG­
FBP-3 levels after 30 months of GH treatment, but not to their 
ratio. The repeated measures model with dose-increment 
steps and duration of treatment as covariates also showed 
that the change in HSDSCA during GH therapy was depen­
dent on IGF-I plasma levels at baseline and during the study 
period (/3 —0.002 and /3 0.0004). The gain in height over 
estimated untreated values at the end of the study (depen­
dent variable) was significantly negatively correlated (P <  
0.0001) w ith age at start of treatm ent The change in PTSrus 
after 4 yr GH (dependent variable) was significantly nega­
tively related with CA or BA retardation at the start of the 
study, as well as with bone maturation during the study 
period. Finally, there was no linear relationship between 1) 
the change in HSDSCA and in the plasma GH AUC at each 
corresponding point in time; 2) the change in IGF-I or IG- 
FBP-3 plasma levels, or in the IGF-I to IGFBP-3 ratio and the 
change in AUC at each corresponding point in time; and 3) 
baseline GHBP levels and baseline CA, HSDSCA, HV, stim­
ulated GH levels. Only GHBP levels and BM1-SDS at the start 
of treatment were related (r = 0.45, P = 0.003).
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TABLE 4. Mean (sd ) of IGF-I, IGFBP-3, and GHBP levels for every treatm ent regimen at baseline, 6 months after initiation of GH 
therapy, and each GH dose-increment, and a t 42 and 48 months of GH treatm ent
Gr Baseline 6 months 18 months 30 months 42 months 48 months
IGF-I (mcg/L) A 76.5 (32.7) 213.9 (97.5) 276.6 (91.2) 371.2 (142.8) 393.1 (124.8) « 512.7(143.7)
B 104.9 (41.2)“ 263.7 (126.4) 363.6 (169.2) 562.3 (227.6)fe 525.3 (168.6) 608.1 (191.6)
C 85.8 (37.7) 245.1 (100.5) 348.0 (170.7) 501.8 (139.7)6 526.5 (154.5)* 678.6 (179.0)6
IGFBP-3 (mg/L) A 2.54 (0.57) 4.15 (0.79) 4.22 (0.86) 4.08 (0.92)
B 2.99 (0.75) 4.71 (1.34) 5.08 (1.26) 4.99 (1.44)
C 2.78 (0.55) 4.29 (0.90) 4.58 (0.97) 4.62 (0.80)
GHBP (pmol/L) A 217.1 (94.0) 201.0 (81.6)
B 256.9 (149.4) 219.8 (95.5)
C 224.1 (140.4) 223.4 (164.8)
Gr, group.
“ Significantly different from group A and C, 
b Change from baseline significant!y different from group A.
D iscussion
Growth response
The present study shows that raising the GH dose in sub­
sequent years results in a significant, dose-dependent in­
crease of linear growth expressed as HV or HSDSCA. After 4 
yr of GH treatment only the higher dose groups B and C 
differed significantly from the constant-dose group A, in 
terras of gain in cm, and expressed as the change in HVSDSCA 
(relative to baseline) and in HSDSCA; however, after 4 yr, 
group C was no longer different from group B. Although 
during the course of the study bone maturation proceeded 
significantly faster than that estimated in untreated girls, 
there was no significant difference between the treatment 
groups. Bone maturation was negatively related with base­
line CA and positively with the degree of BA retardation. The 
gain in height outweighed the increase in bone maturation, 
therefore FH prediction improved markedly, the magnitude 
being dependent on the method used, but not significantly 
different between groups. Age, BA RUS, BA retardation, or 
HSDSCA at start of therapy was not related to the change in 
HSDSCA over 4 yr in this study group aged 2-11 yr. On the 
other hand, the gain in height over estimated untreated val­
ues as well as the change in PTSrus after 4 yr of GH treatment 
were negatively related to prestudy CA, BA RUS, or to the 
change in bone maturation. A repeated measures model 
showed that each yearly change in HSDSca significantly 
correlated with IGF-I plasma levels.
Dose-response studies
Dose-response relationships in GH-deficient patients have 
been described earlier (20). De Muinck Keizer-Schrama et at 
(10) reported in GHD children a significantly higher HVSDS 
and HSDSCA in 17 transfer patients (previously treated with 
12 IU G H /m 2/ week) on 4 vs. 2 IU G H /m 2/ day. Preliminary 
reports in TS indicated that the increase in HV outweighed 
the increase in bone maturation and therefore FH prediction 
was more marked and sustained with higher GH dosages (5, 
7,15). However, a comparison with other studies is difficult 
because of the differences in design and GH dose, entry 
criteria (e.g. a lower limit for GH provocative testing), age at 
start of treatment, variables and duration of study reported, 
and reference populations used. Takano et at (15) investi­
gated two constant GH dosage regimens in prepubertal gixls 
with TS, 0.5 and 1.0 lU /kg /w eek  (comparable with 2 and 4
IU /m 2/day). Dose-dependency was shown by the signifi­
cantly higher mean change in HVSDS (Japanese references) 
during the first 4 yr in the highest dose group, in which the 
dose was similar to group A in the present study, compared 
with the lower dose group. In the fourth year of treatment 
HV in the highest dose-group was no longer significantly 
higher compared with the lower dose-group. The same phe­
nomenon might also develop in our study, since after a 
prolonged period on fixed doses, only the HV in group C 
remained significantly higher compared with group A in 
year 4. Nonetheless, this may already have resulted in a 
substantial difference in height gain. Since the mean change 
in HVSDS during the fourth year (see Table 2) was well above 
zero, the girls still exerted catch-up growth. Only 8 girls 
showed signs of pubertal development at a median age of 
13.2 (range 10.9-15.0) yr. There were no significant differ­
ences between this group and the prepubertal girls with 
respect to growth response and bone maturation after 4 yr 
GH therapy.
Although FH prediction methods all have their inadequa­
cies, it has been shown in a previous report (29) that the 
mIPHRUS and PTSRUS methods have the lowest mean error 
compared with the FH actually reached by girls with TS, 
Furthermore, FH prediction methods should not be used 
during growth promoting therapy, since they are based on 
spontaneous growth. However, since mIPHRUS and PTSrus 
both include CA, BA (RUS), and height for the estimation of 
FH, they reflect the influence of GH on growth as well as 
bone maturation. In the present study both methods showed 
significant increases in mean FH prediction after 4 yr of GH 
therapy, without significant group differences. Only a trend 
towards higher values could be observed in the higher dose- 
group s (B and C) for both the actual and estimated (FH 
prediction) cm gained.
Chaussain et at (6) performed a study in TS (CA ranged 
from 5-15 yr) with a GH dose of 0.7 IU /kg/w eek (about 3 
IU / m2/ day). If HV after 6,12, or 24 months had not doubled, 
this dose was increased by the same amount (to a maximum 
of 2.1 IU/ kg/week). Fourteen of those 24 girls (58%) and 49% 
of all girls in the present study were unable to double their 
HV on 4 IU G H /m 2/day after 6 months, and 71% not after 
1 yr (data not shown). After 3 yr, 12 out of the 22 girls (55%) 
were on the maximum GH dose. In agreement with the 
present study, increasing the GH dose did not lead to an
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acceleration of bone maturation, and FH prediction was 
therefore improved.
►
GH, IGF-I, and their main binding proteins
In general, spontaneous as well as stimulated (3/ 35,36) GH 
levels in prepubertal girls with TS have been reported as 
being near normal (2, 4, 35, 37-39). Despite differences in 
the assays used, both spontaneous and stimulated GH 
plasma levels were comparable with, those in prepubertal 
Dutch TS girls in another study (4). In the present study 
the maximum GH levels after arginine stimulation were 
similar between groups, but the range was very wide (3-74 
mU/L). Fifty-four percent of the girls had a maximum 
level below 20 mU/L, the cut-off point generally accepted 
to define GH deficiency. Although the mean BMI-sd score 
was close to zero in these girls (Table l)y obesity could 
explain the rather low maximal GIT levels in these girls (3, 
40, 41), since a negative correlation between stimulated 
GH levels and baseline BMI-SDS was found. Although 
representing only a single test, stimulated GH levels were 
related to the change in HSDSCA after 4 yr GH treatment 
at the 0.07 level of significance. This is in agreement with 
a report in normal children (42) and in disagreement w ith 
a Japanese report in TS (3).
At baseline, a good correlation between spontaneous 
and stimulated maximum GH levels was observed in a 
subgroup of 12 girls of group C, in accordance with a 
previous report (41). Compared with prepubertal Dutch 
TS girls in an earlier study (4), and assuming a conversion 
factor from jwg/L to m U /L  of 2, maximum GH levels were 
comparable (25.6 vs. 27.6 mU/L), mean 24-h GH levels 
were rather low (4.3 vs. ± 6.0 m U/L), and the mean num ­
ber of peaks was high (10.2 vs. 4.5) in the present study. 
It has been suggested (4) that an elevated spontaneous 
pulse frequency pattern might be associated with rela­
tively low IGF-I levels and slow baseline growth and that 
these girls might benefit most from GH treatment. This 
seems in line with the present study. Furthermore, the 
change in HSDSCA after 4 yr GH treatment was negatively 
related to baseline IGF-I and IGFBP-3 levels (or their s d - 
scores for CA) or their ratio.
In agreement with earlier short-term findings in GHD 
patients (20), a clear-cut increase in maximum GH plasma 
levels and AUC values was observed during GH treatment 
with increasing dosages. The elimination half-time, however, 
was similar between the three GH dosage regimens, sug­
gesting that increasing the GH dose results in a higher bio­
availability of GH without accumulation. In addition, injec­
tion of higher dosages (and volume) did not result in a 
delayed time to maximum plasma GH levels. Nevertheless, 
in this small subgroup of girls the change over time of the 
plasma GH AUC was not significantly related to the corre­
sponding growth response expressed as change in HSDSCA 
nor to the corresponding change in IGF-I or IGFBP-3 levels 
or their ratio.
Except for the 30 months tim e-point in group B, IGF-I 
levels showed a progressive significant increase during the
4 treatment years, which in part can be explained by the 
age-dependency of this measurement. At 48 months only
group C still had significantly higher IGF-I levels (adjusted 
for baseline) than group A (P = 0.008). In a report after 3 yr 
in Japanese girls with TS (43), mean IGF-I levels were sta­
tistically higher with 1 IU GH / kg / wk than with 0.5 IU /k g / 
wk. In the present study the change in IGF-I levels after 4 yr 
GH therapy was dependent on the dose, the duration of 
treatment, and the baseline IGF-I level. Thirty-one percent of 
the girls had plasma IGF-I levels after 4 yr GH of more than 
P95 for norm al girls at the puberta l peak, w ithout signif­
icant differences betw een groups. Only two of these girls 
were younger than 10 yr. At a lower GH dose than used 
in group A in the present study  (0.68 IU /k g /w k )  Ranke et 
al (44) reported 15% of the TS girls to have IGF-I plasma 
levels above the pubertal peak after 1 yr. Moreover, base­
line IGFBP-3 plasm a levels in that study hardly  deviated 
from the normal range, bu t after 1 yr of GH therapy more 
than 20% of the girls had  IGFBP-3 levels above the pubertal 
peak. In the present study, determ ined in the same labo­
ratory, at baseline only 3, and after 30 m onths 23, girls 
(35%) had IGFBP-3 levels greater than  5 m g /L  (P95 at peak 
pubertal level), w ith  a similar distribution between the 
groups. IGFBP-3 w as not determ ined at 42 and 48 months, 
but a plateau seemed to have been reached after 6 months 
of therapy, despite age-dependency of this binding protein 
and a further increase of the GH dose. Baseline log-values 
of IGF-I vs. IGFBP-3 levels show ed a significant positive 
correlation (r = 0.75; P <  0.0001), but also the change of 
these values after 30 m onths from baseline was signifi­
cantly positively correlated (r = 0.25; P = 0.01). This is in 
line w ith earlier findings in TS (44, 45), and not unex­
pected, since both proteins are GI~I dependent. A progres­
sive rise of the IGF-I to IGFBP-3 ratio could be an indicator 
of the grow th response (44). However, after 30 or 48 
m onths of treatm ent neither was a significant relationship 
observed betw een the change in IGF-I to IGFBP-3 ratio and 
the change in HSDSCA, nor was there a significant differ­
ence betw een groups of the change in this ratio, although 
a trend was apparent after 30 months: the m ean change in 
IGF-I to IGFBP-3 ratio was 60, 82, and 81, for group A, B, 
and C. Also, neither IGF-I nor IGFBP-3 levels, nor their 
ratio were related to the pretreatm ent HV(sd score). Taken 
together, there is little evidence to support an explanation 
of the differences in grow th response betw een the groups 
by a change in the IGF-I to IGFBP-3 ratio. Nevertheless, a 
repeated measures model, w ith the dose-increment steps 
and duration  of treatm ent as covariants, show ed that each 
change in HSDSCA correlated significantly with IGF-I 
plasm a levels. Thus, free IGF-I m ight still be a determining 
factor.
In contrast to an earlier study with an older group of girls 
with TS (32), but in agreement with another report in TS (46), 
the decrease in GHBP levels after 6 months treatment was not 
significant from baseline. This might be because of a large 
interindividual variation. At baseline there were no differ­
ences between groups. Most of the girls had GHBP levels 
within the normal age range, as shown previously (34). At 
baseline a linear relationship between GHBP levels and age 
or stimulated GH levels at start of treatment in the present 
group of girls with TS was not observed, in contrast to earlier 
reports in normal children (34). In agreement with the latter
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report, however, GHBP levels at baseline correlated posi­
tively with B M I-sd score.
In conclusion, a stepwise GH-dosing approach reduced 
the waning effect of the growth response after 4 yr treatment 
without undue bone maturation. The increase in FH predic­
tion was not significantly different between treatment 
groups. Irrespective of the GH dose used, initiation of GH 
treatment at a younger age is beneficial in terms of cm gained 
either, at end of study or in terms of predicted FH, but not 
when expressed as the change in HSDSCA over the study 
period. The lower the baseline IGF-I and IGFBP-3 plasma 
levels as well as their ratio, and the higher the change in IGF-I 
and IGFBP-3 plasma levels, the greater is the change in 
HSDSca . The ultimate proof of the effect of the three GFI 
treatment regimens is FH. Therefore, the present treatment 
protocol will be extended until FH is reached.
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